Details of the Drug

General Information of Drug (ID: DM7NPJS)

Drug Name

Paliperidone

Synonyms

Xeplion; Invega Sustenna; Paliperidone palmitate; JNS-010; Paliperidone (depot injection, NanoCrystal); Paliperidone (injectable, NanoCrystal), Elan; Paliperidone (depot injection, NanoCrystal), Johnson & Johnson

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1], [2], [3]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

426.5

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [4]
Bioavailability: The bioavailability of drug is 28% [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.18 mL/min/kg [6]
Elimination: 59% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 23 hours [6]
Metabolism: The drug is not metabolised [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.24% [6]
Vd: The volume of distribution (Vd) of drug is 487 L [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.01125 mg/mL [4]

Chemical Identifiers

Formula: C23H27FN4O3
IUPAC Name: 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Canonical SMILES: CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
InChI: InChI=1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
InChIKey: PMXMIIMHBWHSKN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 115237
ChEBI ID: CHEBI:83804
CAS Number: 144598-75-4
DrugBank ID: DB01267
TTD ID: D0B3UJ
VARIDT ID: DR00159
INTEDE ID: DR1230
ACDINA ID: D00505

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT receptor (5HTR)	TT85JO3	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Paliperidone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Iloperidone.	Schizophrenia [6A20]	[50]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Molindone.	Schizophrenia [6A20]	[51]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Thiothixene.	Schizophrenia [6A20]	[51]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Amisulpride.	Schizophrenia [6A20]	[52]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Asenapine.	Schizophrenia [6A20]	[50]
-----------

Coadministration of a Drug Treating the Disease Different from Paliperidone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[53]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Midostaurin.	Acute myeloid leukaemia [2A60]	[50]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Arn-509.	Acute myeloid leukaemia [2A60]	[54]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[55]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Paliperidone and Oliceridine.	Acute pain [MG31]	[56]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[57]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[57]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Ivabradine.	Angina pectoris [BA40]	[54]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Dronedarone.	Angina pectoris [BA40]	[50]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Paliperidone and Amyl nitrite.	Angina pectoris [BA40]	[58]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[59]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Levalbuterol.	Asthma [CA23]	[60]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Pirbuterol.	Asthma [CA23]	[61]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Retigabine.	Behcet disease [4A62]	[50]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Eribulin.	Breast cancer [2C60-2C6Y]	[50]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[62]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[61]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[60]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[61]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[61]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Paliperidone and Dihydrocodeine.	Chronic pain [MG30]	[63]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Probucol.	Coronary atherosclerosis [BA80]	[50]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Pasireotide.	Cushing syndrome [5A70]	[50]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Osilodrostat.	Cushing syndrome [5A70]	[54]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Paliperidone and Cyclandelate.	Dementia [6D80-6D8Z]	[58]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Paliperidone and OPC-34712.	Depression [6A70-6A7Z]	[51]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Paliperidone and Esketamine.	Depression [6A70-6A7Z]	[64]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Mepenzolate.	Digestive system disease [DE2Z]	[51]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[65]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Deutetrabenazine.	Dystonic disorder [8A02]	[66]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Ingrezza.	Dystonic disorder [8A02]	[67]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Solifenacin.	Functional bladder disorder [GC50]	[50]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[50]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Paliperidone and Penbutolol.	Hypertension [BA00-BA04]	[58]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Paliperidone and Nebivolol.	Hypertension [BA00-BA04]	[58]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Paliperidone and Levamlodipine.	Hypertension [BA00-BA04]	[58]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Paliperidone and TAK-491.	Hypertension [BA00-BA04]	[58]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Paliperidone and Hydralazine.	Hypertension [BA00-BA04]	[58]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Paliperidone and Clevidipine butyrate.	Hypertension [BA00-BA04]	[58]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[51]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Paliperidone and ITI-007.	Insomnia [7A00-7A0Z]	[51]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[50]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[50]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Paliperidone caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[54]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Crizotinib.	Lung cancer [2C25]	[69]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Ceritinib.	Lung cancer [2C25]	[50]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Osimertinib.	Lung cancer [2C25]	[70]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Selpercatinib.	Lung cancer [2C25]	[54]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Lumefantrine.	Malaria [1F40-1F45]	[64]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Hydroxychloroquine.	Malaria [1F40-1F45]	[71]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[54]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Vemurafenib.	Melanoma [2C30]	[50]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and LGX818.	Melanoma [2C30]	[72]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Paliperidone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[73]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Paliperidone and Lasmiditan.	Migraine [8A80]	[74]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Paliperidone and Flibanserin.	Mood disorder [6A60-6E23]	[75]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Panobinostat.	Multiple myeloma [2A83]	[76]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Siponimod.	Multiple sclerosis [8A40]	[64]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Fingolimod.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Ozanimod.	Multiple sclerosis [8A40]	[77]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Romidepsin.	Mycosis fungoides [2B01]	[50]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[50]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Phenindamine.	Nasopharyngitis [CA00]	[51]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Entrectinib.	Non-small cell lung cancer [2C25]	[64]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Paliperidone and Lorcaserin.	Obesity [5B80-5B81]	[78]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Paliperidone and Polythiazide.	Oedema [MG29]	[64]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Paliperidone and Lofexidine.	Opioid use disorder [6C43]	[50]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Rucaparib.	Ovarian cancer [2C73]	[50]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Triclabendazole.	Parasitic worm infestation [1F90]	[50]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Paliperidone when combined with Opicapone.	Parkinsonism [8A00]	[79]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Pimavanserin.	Parkinsonism [8A00]	[80]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Methylscopolamine.	Peptic ulcer [DA61]	[51]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[81]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Lefamulin.	Pneumonia [CA40]	[82]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Degarelix.	Prostate cancer [2C82]	[54]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and ABIRATERONE.	Prostate cancer [2C82]	[54]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Enzalutamide.	Prostate cancer [2C82]	[54]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Relugolix.	Prostate cancer [2C82]	[54]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[50]
Neupro	DMHEAB1	Moderate	Additive CNS depression effects by the combination of Paliperidone and Neupro.	Restless legs syndrome [7A80]	[79]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Paliperidone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[50]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[50]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[54]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Pitolisant.	Somnolence [MG42]	[50]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[50]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Paliperidone and Lenvatinib.	Thyroid cancer [2D10]	[50]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Paliperidone and Cabozantinib.	Thyroid cancer [2D10]	[54]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Paliperidone and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[51]
-----------


⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia	E00007	222	Alkalizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Paliperidone 9 mg tablet	9 mg	24 HR Extended Release Oral Tablet	Oral
Paliperidone 1.5 mg tablet	1.5 mg	24 HR Extended Release Oral Tablet	Oral
Paliperidone 3 mg tablet	3 mg	24 HR Extended Release Oral Tablet	Oral
Paliperidone 6 mg tablet	6 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7258).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	ClinicalTrials.gov (NCT02146547) European Long-acting Antipsychotics in Schizophrenia Trial. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8	Invega (paliperidone) extended release tablets FDA Label
9	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.
10	Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
11	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
30	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
31	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
32	Drug Interactions Flockhart Table
33	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
34	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
35	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
36	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
37	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
38	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
40	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
41	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
42	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
43	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
44	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
45	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
46	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
47	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
48	Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
49	ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
50	Canadian Pharmacists Association.
51	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
52	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
53	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
54	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
56	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
57	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
58	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
59	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
60	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
61	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
62	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
64	Cerner Multum, Inc. "Australian Product Information.".
65	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
66	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
67	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
68	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
69	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
72	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
73	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
74	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
75	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
76	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
77	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
78	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
79	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
80	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
81	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
82	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.